• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

完全无活性的血浆肾素原的分离及其被激肽释放酶激活。肾素与激肽释放酶之间可能存在的新联系。

Isolation of completely inactive plasma prorenin and its activation by kallikreins. A possible new link between renin and kallikrein.

作者信息

Yokosawa N, Takahashi N, Inagami T, Page D L

出版信息

Biochim Biophys Acta. 1979 Aug 15;569(2):211-9. doi: 10.1016/0005-2744(79)90056-1.

DOI:10.1016/0005-2744(79)90056-1
PMID:476126
Abstract

Existing views on prorenin are conflicting and its physiological activation mechanism is not clear. In an attempt to obtain clearcut views on the molecular properties of prorenin in human plasma, the renin zymogen (prorenin) was separated from active renin by two steps of affinity chromatography and it was demonstrated that prorenin is a completely inactivate zymogen contrary to the existing information. Inactive prorenin has an apparent molecular of 56,000 contrary to 46,000-43,000 of partially active prorenin. Isolated and acid-treated human prorenin was shown to be activated by kallikreins from human urine and plasma. This activation was completely blocked by Trasylol. Hog pancreatic kallikrein also activated human prorenin. The kallikrein mediated activation of prorenin indicates the existence of a new link between the vasoconstricting renin-angiotensin system and the vasodilating kallikreinkinin system.

摘要

目前关于肾素原的观点相互矛盾,其生理激活机制尚不清楚。为了明确人血浆中肾素原的分子特性,通过两步亲和层析法将肾素酶原(肾素原)与活性肾素分离,并证明肾素原是一种完全无活性的酶原,这与现有信息相反。无活性肾素原的表观分子量为56,000,而部分活性肾素原的分子量为46,000 - 43,000。分离并经酸处理的人肾素原可被人尿液和血浆中的激肽释放酶激活。这种激活被抑肽酶完全阻断。猪胰激肽释放酶也能激活人肾素原。激肽释放酶介导的肾素原激活表明血管收缩性肾素 - 血管紧张素系统与血管舒张性激肽释放酶 - 激肽系统之间存在新的联系。

相似文献

1
Isolation of completely inactive plasma prorenin and its activation by kallikreins. A possible new link between renin and kallikrein.完全无活性的血浆肾素原的分离及其被激肽释放酶激活。肾素与激肽释放酶之间可能存在的新联系。
Biochim Biophys Acta. 1979 Aug 15;569(2):211-9. doi: 10.1016/0005-2744(79)90056-1.
2
Partial purification of prorenin and activation by kallikreins: a possible new link between renin and kallikrein systems.肾素原的部分纯化及激肽释放酶的激活:肾素与激肽释放酶系统之间可能的新联系。
Adv Exp Med Biol. 1979;120B:415-28.
3
Plasma kallikrein-mediated activation of the renin-angiotensin system does not require prior acidification of prorenin.血浆激肽释放酶介导的肾素-血管紧张素系统激活并不需要肾素原预先酸化。
J Clin Endocrinol Metab. 1982 Feb;54(2):343-8. doi: 10.1210/jcem-54-2-343.
4
Initiation of plasma prorenin activation by Hageman factor-dependent conversion of plasma prekallikrein to kallikrein.通过Hageman因子依赖性地将血浆前激肽释放酶转化为激肽释放酶来启动血浆肾素原激活。
Proc Natl Acad Sci U S A. 1979 Nov;76(11):5914-8. doi: 10.1073/pnas.76.11.5914.
5
An inactive, prorenin-like substance in human kidney and plasma.人肾脏和血浆中的一种无活性的、肾素原样物质。
Clin Sci (Lond). 1980 Dec;59 Suppl 6:29s-33s. doi: 10.1042/cs059029s.
6
Characterization of prorenin activation using a synthetic peptide substrate.使用合成肽底物对肾素原激活进行表征。
J Hypertens. 1991 Jun;9(6):483-6. doi: 10.1097/00004872-199106000-00001.
7
Role of glandular kallikrein in the activation process of human plasma inactive renin.腺激肽释放酶在人血浆无活性肾素激活过程中的作用
Hypertension. 1983 Mar-Apr;5(2):191-7. doi: 10.1161/01.hyp.5.2.191.
8
Evidence for a role of plasma kallikrein in the activation of prorenin.血浆激肽释放酶在肾素原激活中作用的证据。
Nature. 1980 Jan 31;283(5746):482-3. doi: 10.1038/283482a0.
9
Plasma kallikrein and prorenin in patients with hereditary angioedema.遗传性血管性水肿患者的血浆激肽释放酶和肾素原
J Lab Clin Med. 1985 Jun;105(6):694-9.
10
Rat renal and plasma prorenin are activated in vitro by different mechanisms.
Hypertension. 1999 Sep;34(3):520-4. doi: 10.1161/01.hyp.34.3.520.

引用本文的文献

1
The renin-angiotensin system biomolecular cascade: a 2022 update of newer insights and concepts.肾素-血管紧张素系统生物分子级联反应:2022年最新见解与概念更新
Kidney Int Suppl (2011). 2022 Apr;12(1):36-47. doi: 10.1016/j.kisu.2021.11.002. Epub 2022 Mar 18.
2
Angiotensin-converting enzyme 2, the complement system, the kallikrein-kinin system, type-2 diabetes, interleukin-6, and their interactions regarding the complex COVID-19 pathophysiological crossroads.血管紧张素转换酶 2、补体系统、激肽释放酶-激肽系统、2 型糖尿病、白细胞介素 6 及其相互作用在复杂的 COVID-19 病理生理学交汇点。
J Renin Angiotensin Aldosterone Syst. 2020 Oct-Dec;21(4):1470320320979097. doi: 10.1177/1470320320979097.
3
Determinants of the unusual cleavage specificity of lysyl-bradykinin-releasing kallikreins.
赖氨酰缓激肽释放激肽释放酶异常切割特异性的决定因素。
Biochem J. 1995 Feb 15;306 ( Pt 1)(Pt 1):63-9. doi: 10.1042/bj3060063.
4
A qualitative difference in plasma renin activity in Dahl rats susceptible or resistant to salt-induced hypertension.对盐诱导高血压敏感或耐受的 Dahl 大鼠血浆肾素活性的质的差异。
Biochem Genet. 1980 Dec;18(11-12):1087-96. doi: 10.1007/BF00484340.
5
Human plasma kallikrein. A rapid purification method with high yield.人血浆激肽释放酶。一种高产率的快速纯化方法。
Biochem J. 1981 Jan 1;193(1):187-92. doi: 10.1042/bj1930187.
6
Confirmation of direct angiotensin formation by kallikrein.激肽释放酶直接生成血管紧张素的证实。
Biochem J. 1983 Jul 1;213(1):193-200. doi: 10.1042/bj2130193.
7
Characterization of inactive renin ("prorenin") from renin-secreting tumors of nonrenal origin. Similarity to inactive renin from kidney and normal plasma.非肾源性肾素分泌肿瘤中无活性肾素(“前肾素”)的特性。与来自肾脏和正常血浆的无活性肾素的相似性。
J Clin Invest. 1984 Feb;73(2):437-47. doi: 10.1172/JCI111230.
8
Characterization of inactive renin from human kidney and plasma. Evidence of a renal source of circulating inactive renin.人肾和血浆中无活性肾素的特性。循环中无活性肾素来源于肾脏的证据。
J Clin Invest. 1983 Mar;71(3):506-17. doi: 10.1172/jci110795.
9
Coexistence of renin and cathepsin B in epithelioid cell secretory granules.肾素与组织蛋白酶B在类上皮细胞分泌颗粒中的共存。
Histochemistry. 1985;83(2):103-8. doi: 10.1007/BF00495138.
10
Initiation of plasma prorenin activation by Hageman factor-dependent conversion of plasma prekallikrein to kallikrein.通过Hageman因子依赖性地将血浆前激肽释放酶转化为激肽释放酶来启动血浆肾素原激活。
Proc Natl Acad Sci U S A. 1979 Nov;76(11):5914-8. doi: 10.1073/pnas.76.11.5914.